Nimesulide in the treatment of advanced cancer pain : double-blind comparison with naproxen

In a clinical double-blind study, the analgesic efficacy and the side-effects of nimesulfide (Aulin ®, CAS 51803-78-2) and naproxen administered to 68 patients affected by advanced cancer pain were compared. Patients were treated with non-steroidal anti-inflammatory drugs according to the first step of the pharmacological analgesic scale of the WHO. The dose adminsitrated was 200 mg b.i.d. (every 12 h) for nimesulide and 500 mg b.i.d. (every 12 h) for naproxen